Bertram Capital Adds to Compliance Services Portfolio Through Partnership with Medical Technology Associates
FOSTER CITY, Calif., Nov. 17, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Bertram Capital Adds to Compliance Services Portfolio Through Partnership with Medical Technology Associates
PR Newswire
FOSTER CITY, Calif., Nov. 17, 2026
FOSTER CITY, Calif., Nov. 17, 2026 /PRNewswire/ — Bertram Capital (“Bertram”) announced today its investment in Medical Technology Associates (“MTA” or the “Company”), a leading national provider of regulatory-driven compliance services to healthcare and life sciences customers. MTA provides testing, inspection, certification, repair, and replacement services across medical gas, controlled environment, calibration, biomedical, and laboratory testing applications. Bertram’s investment will support the continued expansion of MTA’s technician base, service capabilities, and geographic coverage. MTA represents Bertram’s eighth platform investment in Fund V. Terms of the transaction were not disclosed.
Headquartered in Pinellas Park, Florida, MTA’s team of more than 150 technicians serves healthcare and life science customers nationwide, including hospitals, health systems, pharmacies, and laboratories. MTA operates through a family of specialized brands under a single compliance standard, with ASSE, CETA, NSF, and NEBB credentialed technicians and ISO 17025 accredited calibration capabilities that help customers meet recurring testing and certification requirements under NFPA 99, CMS, Joint Commission, and USP standards.
“MTA has established itself as a trusted compliance partner to hospitals and health systems nationwide, combining the technician capacity, regulatory expertise, and responsiveness customers rely on to keep life safety systems compliant and operating safely,” said Jared Ruger, Partner at Bertram Capital. “The Company’s breadth of services positions it well to serve customers as one partner across their compliance needs. We are excited to partner with Allan and the MTA team to continue expanding the Company’s geographic presence and service portfolio, both organically and through acquisitions.”
Bertram acquired MTA from Riverarch Equity Partners (“Riverarch”), which acquired the Company in 2022. Allan Morris will continue to lead MTA as Chief Executive Officer, and the existing leadership team will remain in place and retain meaningful ownership in the Company. Bertram brings deep experience supporting acquisition-driven services platforms, as well as the resources of Bertram Labs, its in-house technology team.
“Over the past several years, we have built the MTA platform to become a single-source compliance partner for our customers, and Bertram stood out based on its understanding of our business and its track record helping companies scale through acquisitions. With the assistance of Bertram Labs, we also see significant opportunities to enhance the way we serve our customers and support our technicians. Most importantly, we look forward to working alongside a partner that values our people, shares our culture, and supports our vision,” said Allan Morris, CEO of MTA.
Bertram would like to recognize the investment banking team at Houlihan Lokey, MTA’s sell-side advisor, led by Casey Schwartz and Ranon Kent, for their efforts in this transaction. Bertram also thanks Steve Nelson and Mike Strupe of Intrepid Investment Bankers for their support as buy-side advisor, Andrew Lohmann and Lisa Hedrick at Hirschler for their support as legal counsel, and Golub Capital and BTG Pactual Strategic Capital. for providing financing in support of the transaction.
About Medical Technology Associates
Headquartered in Pinellas Park, Florida, MTA is one of the largest healthcare testing, inspection, certification, repair, and calibration companies in the United States. In addition to servicing medical gas systems, MTA provides a comprehensive suite of calibration, biomedical equipment, controlled environment, and laboratory testing solutions, including clean room and hood certification for pharmacies and laboratories. For more information, visit mtausa.com.
About Bertram Capital
Bertram Capital is a private equity firm targeting investments in lower middle-market companies. Since its inception in 2006, the firm has raised over $4.0 billion in capital commitments. In addition to providing strategic growth capital, Bertram Capital seeks to leverage proprietary processes and services, Bertram High-5℠ and Bertram Labs, to empower its portfolio companies to unlock their full potential.
Bertram High-5℠ is an operationally focused value-creation strategy that includes management augmentation, operational initiatives, complementary acquisitions, sales and marketing improvements, and technology integration. The cornerstone of this strategy is Bertram Labs, its in-house technology team, which drives growth through digital marketing, e-commerce, big data and analytics, application development, and platform optimization.
Bertram Capital V focuses on control investments in business services, consumer, and industrial sectors with EBITDA above $7.5 million. Bertram Ignite I focuses on both control and non-control investments in similar sectors, with a minimum EBITDA of $3 million.
For more information, visit www.bcap.com.
About Riverarch Equity Partners
Riverarch is a middle-market private equity firm that invests in market-leading businesses where it can partner with management to support accelerated growth. The firm is based in Pittsburgh, Pennsylvania.
Media Contact
David Hellier
pr@bcap.com
650-358-5000
View original content to download multimedia:https://www.prnewswire.com/news-releases/bertram-capital-adds-to-compliance-services-portfolio-through-partnership-with-medical-technology-associates-302941454.html
SOURCE Bertram Capital


